Intellipharmaceutics International Inc. said the Nasdaq Hearings Panel granted its request for continued listing while it works to regain compliance with the exchange's listing requirements.
The Toronto-based drugmaker has until Sept. 28 to comply with the Nasdaq's $1 bid price and $2.5 million stockholder's equity requirements. Intellipharmaceutics also needs to submit its updated financial projections showing it can maintain compliance.
